jmboehm/RegressionTables.jl: v0.6.2

<h2>RegressionTables v0.6.2</h2> <p><a href="https://github.com/jmboehm/RegressionTables.jl/compare/v0.6.1...v0.6.2">Diff since v0.6.1</a></p> <p><strong>Merged pull requests:</strong></p> <ul> <li>Add option to use original coefficient names in arguments (#148) (@junder873)</li> </ul> <p><strong>Closed issues:</strong></p> <ul> <li>using term instead of @formula from FixedEffectModels causes an error (#142)</li> <li>Confusion extending regtable for different type of RegressionModel (#144)</li> <li><code>keep</code> option uses post-processing variable names: document or change? (#147)</li> </ul&gt

jmboehm/RegressionTables.jl: v0.7.0

<h2>RegressionTables v0.7.0</h2> <p><a href="https://github.com/jmboehm/RegressionTables.jl/compare/v0.6.2...v0.7.0">Diff since v0.6.2</a></p> <p><strong>Merged pull requests:</strong></p> <ul> <li>Change how below statistics work to make more flexible (#146) (@junder873)</li> </ul> <p><strong>Closed issues:</strong></p> <ul> <li>bootstrap confidence intervals (#145)</li> </ul&gt

jmboehm/RegressionTables.jl: v0.7.3

<h2>RegressionTables v0.7.3</h2> <p><a href="https://github.com/jmboehm/RegressionTables.jl/compare/v0.7.2...v0.7.3">Diff since v0.7.2</a></p> <p><strong>Merged pull requests:</strong></p> <ul> <li>Add support for Typst tables (#141) (@junder873)</li> </ul&gt

jmboehm/RegressionTables.jl: v0.7.5

<h2>RegressionTables v0.7.5</h2> <p><a href="https://github.com/jmboehm/RegressionTables.jl/compare/v0.7.4...v0.7.5">Diff since v0.7.4</a></p> <p><strong>Merged pull requests:</strong></p> <ul> <li>Use StatsAPI.confint instead of custom confidence interval function (#155) (@junder873)</li> </ul&gt

jmboehm/RegressionTables.jl: v0.7.1

<h2>RegressionTables v0.7.1</h2> <p><a href="https://github.com/jmboehm/RegressionTables.jl/compare/v0.7.0...v0.7.1">Diff since v0.7.0</a></p> <p><strong>Merged pull requests:</strong></p> <ul> <li>Use Format.jl instead of Formatting.jl to fix bugs (#149) (@ScottPJones)</li> </ul&gt

Influence of antibiotic therapy with hemodynamic optimization on 30-day mortality among septic shock patients cared for in the prehospital setting

International audienceIn order to reduce septic shock mortality, international guidelines recommend early treatment implementation, antibiotic therapy (ABT) and hemodynamic optimisation, within 1-h. This retrospective multicentric study aims to investigate the relationship between prehospital ABT delivered within 1st hour and mean blood pressure (MAP) ≥ 65 mmHg at the end of the prehospital stage, and 30-day mortality among patients with septic shock. Methods: From May 2016 to December 2021, patients with septic shock requiring pre-hospital Mobile Intensive Care Unit intervention (MICU) were retrospectively analysed. To assess the relationship between 30-day mortality and prehospital ABT delivered within 1st hour and/or MAP ≥ 65 mmHg at the end of the prehospital stage, Inverse Probability Treatment Weighting (IPTW) propensity score method was performed. Results: Among the 530 patients included, 341 were male gender (64%) with a mean age of 69 ± 15 years. One-hundred and thirty-two patients (25%) patients received prehospital ABT, among which 98 patients (74%) were treated with 3rd generation cephalosporin. Suspected pulmonary, urinary and digestive infections were the cause of sepsis in respectively 43%, 25% and 17%. The 30-day overall mortality was 31%. A significant association was observed between 30-day mortality rate and (i) ABT administration within the first hour: RRa = 0.14 [0.04u20130.55], (ii) ABT administration within the first hour associated with a MAP ≥ 65 mmHg: RRa = 0.08 [0.02u20130.37] and (iii) ABT administration within the first hour in the prehospital setting associated with a MAP < 65 mmHg at the end of the prehospital stage: RRa = 0.75 [0.45u20130.85]. Patients who received prehospital ABT after the first hour have also a 30-day mortality rate decrease: RRa = 0.87 [0.57u20130.99], whereas patients who did not received ABT had an increased 30-day mortality rate: RRa = 2.36 [1.89u20132.95]. Conclusion: In this study, we showed that pre-hospital ABT within the first hour and MAP≥65 mmHg at the end of prehospital stage are both associated with 30-day mortality decrease among patients suffering from septic shock cared for by a MICU. Further prospective studies are needed to confirm these preliminary results

jmboehm/RegressionTables.jl: v0.7.4

<h2>RegressionTables v0.7.4</h2> <p><a href="https://github.com/jmboehm/RegressionTables.jl/compare/v0.7.3...v0.7.4">Diff since v0.7.3</a></p> <p><strong>Merged pull requests:</strong></p> <ul> <li>Fix BIC calling aaic instead of bic (#154) (@junder873)</li> </ul> <p><strong>Closed issues:</strong></p> <ul> <li>Documentation seems to suggest conflicting argument types for <code>regression_statistics</code> and neither example works in practice: please reproduce? (#152)</li> </ul&gt

jmboehm/RegressionTables.jl: v0.7.2

<h2>RegressionTables v0.7.2</h2> <p><a href="https://github.com/jmboehm/RegressionTables.jl/compare/v0.7.1...v0.7.2">Diff since v0.7.1</a></p> <p><strong>Merged pull requests:</strong></p> <ul> <li>Add vertical gaps function (#151) (@junder873)</li> </ul&gt

Cold Agglutinin Syndrome Secondary to Mycoplasma pneumoniae Infection in Adults: Results From a Large French Observational Study ( MyCOLD Study)

International audienceMycoplasma pneumoniae ( MP ), primarily a respiratory pathogen, can cause extra‐pulmonary manifestations including cold agglutinin syndrome (CAS). We conducted a national, multicenter, observational, ambispective study to describe the characteristics, risk factors, and outcomes of MP ‐associated CAS. Adult patients hospitalized for a MP‐ infection with CAS (hemolytic anemia with hemoglobin < 10 g/dL and C3 positive direct anti‐globulin test) were included. Recovery was defined as hemoglobin > 10 g/dL off therapy. We also compared MP ‐infected patients with or without CAS. Sixty patients (51.7% of females; median age of 48.5 years) were included. CAS was diagnosed a median of 10 days after MP‐ infection symptoms onset. At diagnosis, the median hemoglobin level was 6.9 g/dL, and 71.7% of patients received red blood cell transfusions. Intensive care unit (ICU) admission was required in 45% of patients, and 16.7% experienced a venous thromboembolic event (VTE). Seventeen patients (28.3%) received glucocorticoids alone, while 40 (66.7%) did not receive any specific treatment for CAS. After a median follow‐up of 56 (30–83) days, 90% of patients achieved recovery, while 2 patients (3.3%) died from sepsis and pulmonary embolism. Glucocorticoid use did not significantly impact the rate or timing of recovery. Compared with MP ‐infected patients from the MYCADO cohort study ( n = 1267), CAS patients had significantly more VTE ( p < 0.0001) and ICU admissions ( p = 0.03). MP ‐associated CAS typically occurs 10 days after the first symptoms of MP infection and is associated with ICU admissions and VTE. Overall, the prognosis of CAS is good, and glucocorticoids do not appear to influence outcomes